These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hepatic injury due to troglitazone. Malik AH; Prasad P; Saboorian MH; Thiele DL; Malet PF Dig Dis Sci; 2000 Jan; 45(1):210-4. PubMed ID: 10695637 [No Abstract] [Full Text] [Related]
3. Substituting for troglitazone (Rezulin). Med Lett Drugs Ther; 2000 Apr; 42(1076):36. PubMed ID: 10803176 [No Abstract] [Full Text] [Related]
4. Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings. Li H; Heller DS; Leevy CB; Zierer KG; Klein KM J Diabetes Complications; 2000; 14(3):175-7. PubMed ID: 10989325 [TBL] [Abstract][Full Text] [Related]
6. Fatal hepatotoxicity associated with troglitazone. Vella A; de Groen PC; Dinneen SF Ann Intern Med; 1998 Dec; 129(12):1080. PubMed ID: 9867776 [No Abstract] [Full Text] [Related]
7. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. Fukano M; Amano S; Sato J; Yamamoto K; Adachi H; Okabe H; Fujiyama Y; Bamba T Hum Pathol; 2000 Feb; 31(2):250-3. PubMed ID: 10685643 [TBL] [Abstract][Full Text] [Related]
8. Diabetes drug Rezulin: take it, but take precautions. Health News; 1999 May; 5(6):7. PubMed ID: 10546576 [No Abstract] [Full Text] [Related]
9. Severe but reversible hepatitis induced by troglitazone. Schiano T; Dolehide K; Hart J; Baker AL Dig Dis Sci; 2000 May; 45(5):1039-42. PubMed ID: 10795774 [No Abstract] [Full Text] [Related]
10. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Gitlin N; Julie NL; Spurr CL; Lim KN; Juarbe HM Ann Intern Med; 1998 Jul; 129(1):36-8. PubMed ID: 9652997 [No Abstract] [Full Text] [Related]
11. Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis. Lenhard MJ; Funk WB Diabetes Care; 2001 Jan; 24(1):168-9. PubMed ID: 11194222 [No Abstract] [Full Text] [Related]
14. An autopsy case of troglitazone-induced fulminant hepatitis. Shibuya A; Watanabe M; Fujita Y; Saigenji K; Kuwao S; Takahashi H; Takeuchi H Diabetes Care; 1998 Dec; 21(12):2140-3. PubMed ID: 9839107 [TBL] [Abstract][Full Text] [Related]
15. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Kohlroser J; Mathai J; Reichheld J; Banner BF; Bonkovsky HL Am J Gastroenterol; 2000 Jan; 95(1):272-6. PubMed ID: 10638596 [TBL] [Abstract][Full Text] [Related]
16. Lessons from the glitazones: a story of drug development. Gale EA Lancet; 2001 Jun; 357(9271):1870-5. PubMed ID: 11410214 [TBL] [Abstract][Full Text] [Related]
17. FDA reviews troglitazone. Donnelly R Diabetes Obes Metab; 1999 Mar; 1(2):65-6. PubMed ID: 11220513 [No Abstract] [Full Text] [Related]
18. Rapid-onset subfulminant liver failure associated with troglitazone. Jagannath S; Rai R Ann Intern Med; 2000 Apr; 132(8):677. PubMed ID: 10766693 [No Abstract] [Full Text] [Related]
19. A novel antidiabetic drug, troglitazone--reason for hope and concern. Imura H N Engl J Med; 1998 Mar; 338(13):908-9. PubMed ID: 9516229 [No Abstract] [Full Text] [Related]
20. [Meta-analysis shows: insulin sensitizer is safe for the liver]. MMW Fortschr Med; 2002 Oct; 144(40):47. PubMed ID: 12440297 [No Abstract] [Full Text] [Related] [Next] [New Search]